secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091205
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q2 net loss $58.7M; Phase 3 MDD data on track for Q4 2024
-----------------------------------------------------------------

- Cash $371.6M as of June 30, 2024, expected to fund operations into 2026.
- R&D expense $48.6M (up from $32.8M); G&A $15.2M (up from $9.3M).
- Topline data from KOASTAL-1 Phase 3 study of navacaprant in MDD expected Q4 2024.
- Phase 2 trial for navacaprant in bipolar depression initiated; Phase 1b of NMRA-511 in Alzheimer's agitation started.
- NMRA-266 study on clinical hold; additional M4 PAM IND submission expected first half 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000095017024091205/0000950170-24-091205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000095017024091205/nmra-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer